Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193492 · ClinicalTrials.gov registry record · Phase 2
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, Follicular, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT00193492: Completed Phase 2 study of Lymphoma, Follicular, sponsored by SCRI Development Innovations.
NCT00193492 is a Phase 2 study of Lymphoma, Follicular that has completed, run by SCRI Development Innovations. The registered enrollment target is 60 participants, below the 125-participant average among 9 other Lymphoma, Follicular trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00193492, a Phase 2 study of Lymphoma, Follicular, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the feasibility, efficacy and safety of adding bevacizumab to rituximab compared to rituximab alone in patients with previously treated follicular non-hodgkin's lymphoma (NHL) whose disease has progressed following at least one previous chemotherapy regimen and not more than 2 previous chemotherapy regimens.
Primary Outcome
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Rituximab
Study Locations (20)
Florida
- Florida Cancer Specialists - Fort Myers
- Integrated Community Oncology Network - Jacksonville
- Watson Clinic for Cancer Research - Lakeland
- Florida Hospital Cancer Institute - Orlando
Georgia
- Medical Oncology Associates of Augusta - Augusta
- Northeast Georgia Medical Center - Gainesville
- Wellstar Cancer Research - Marietta
Kentucky
- Graves-Gilbert Clinic - Bowling Green
- Baptist Hospital East - Louisville
- Norton Cancer Institute - Louisville
Maryland
- Center for Cancer and Blood Disorders - Bethesda
- National Capital Clinical Research Consortium - Bethesda
Arkansas
- Northeast Arkansas Clinic - Jonesboro
Indiana
- Providence Medical Group - Terre Haute
Louisiana
- Hematology Oncology Clinic, LLP - Baton Rouge
Nebraska
- Methodist Cancer Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-09 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
What the finished NCT00193492 record still lists
NCT00193492 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 125-participant average among 9 other Lymphoma, Follicular trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Lymphoma, Follicular appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00193492 names 20 study sites across 12 states, led by Florida, Georgia, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00193492 about?
NCT00193492 is a clinical study titled "A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma". The purpose of this study is to assess the feasibility, efficacy and safety of adding bevacizumab to rituximab compared to rituximab alone in patients with previously treated follicular non-hodgkin's lymphoma (NHL) whose disease has progressed following at least one previous chemotherapy regimen and...
What is the current status of trial NCT00193492?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2005-09. Estimated completion is 2013-03.
What conditions does trial NCT00193492 study?
This clinical trial studies the following conditions: Lymphoma, Follicular.
What interventions are being tested in trial NCT00193492?
The interventions under investigation include: Bevacizumab (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT00193492?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00193492 being conducted?
This trial has 20 study locations across Arkansas, Florida, Georgia, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Follicular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00193492's enrollment target sits among peer trials
60 7th of 9 higher than 3 of 9 other Lymphoma, Follicular trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, Follicular trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
COMPLETED · Phase 2
-
A Study of Enzastaurin in Participants With Follicular Lymphoma
COMPLETED · Phase 2
-
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
COMPLETED · Phase 2
-
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia